Document is current
Any future updates will be listed below
-
Authors
Jemaa, S.
Paulson, J. N.
Hutchings, M.
Kostakoglu, L.
Trotman, J.
Tracy, S.
de Crespigny, A.
Carano, R. A. D.
El-Galaly, T. C.
Nielsen, T. G.
Bengtsson, T. http://orcid.org/0000-0002-9667-8873
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche
- License Information
-
More Information
Article History
Received: 9 March 2022
Accepted: 17 July 2022
First Online: 12 August 2022
Declarations
:
: This study analyzed data from the randomized phase III GOYA trial (NCT01287741). The trial was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization of Good Clinical Practice guidelines. Trial protocol approval was obtained from the ethics committee/institutional review board at each participating institution and written informed consent to participate was provided by all patients.
: Not applicable.
: S.J and J.N.P are employees of Genentech, Inc. and stockholders of F. Hoffmann-La Roche Ltd. M.H reports no conflicts of interest. L.K is a consultant for F. Hoffmann-La Roche Ltd and Genentech, Inc. and reports travel expenses from F. Hoffmann-La Roche Ltd. J.T reports research funding from F. Hoffmann-La Roche Ltd., Celgene, Janssen, PCYC and Beigene. S.T is an employee of Genentech, Inc. and F. Hoffmann-La Roche Ltd and a stockholder of F. Hoffmann-La Roche Ltd. A.D.C and R.A.D.C are employees of Genentech, Inc. and stockholders of F. Hoffmann-La Roche Ltd. T.C.E–G was an employee of F. Hoffmann-La Roche Ltd. T.N is an employee and stockholder of F. Hoffmann-La Roche Ltd. T.B was an employee of Genentech, Inc. at the time of the manuscript completion. No other potential conflicts of interest relevant to this article exist.
